Funding agency ICMR

Start date Aug. 1, 2020

End Date July 31, 2023

Duration Three Year + 6 month no cost extension

Disease category Trigeminal Neuralgia

Type of study Animal study

Type of data Quantitative data

Aims of objective 1. Preparation of surface-modified PLGA nanoparticles for Gabapentin, Clonazepam, Pregabalin, and Baclofen for controlling the pain 2. Characterization of nanoparticles: entrapment efficiency, drug loading, particle size, size distribution, zeta potential, stability studies 3. In vitro studies (In vitro permeation studies, in vitro cytotoxicity studies, and in vitro cytokines analysis on mammalian cell lines). 4. Pharmacokinetic studies in rats for assessing ADME

Keyword Nanoparticles, Gabapentin, Pregabalin, Baclofen, Clonazepam, Phamacokinetic study, ADME analysis, Trigeminal Neuralgia

Description Since a major bottleneck in brain drug delivery is the presence of blood-brain barrier and other membranes which protect and maintain a uniform environment in the brain, we are proposing an intranasal approach as it bypasses the BBB and has a faster onset of action that would provide relief to patients of trigeminal neuralgia in emergency conditions when the pain is triggered. In addition, since TN is a chronic condition, drugs given via nasal route would reach directly to the brain, leading to lower DOSE requirements and lesser incidences of side effects.

Total Sanctioned budget 43,37,854/-